Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
|---|---|---|---|---|---|---|---|---|---|---|
| HCC1806 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 1.0500 | -0.0207 | -0.0033 | 0.0000 | Inf | -0.67606 |
| HCC1806 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.8168 | 0.1972 | 0.0004 | 0.0000 | Inf | -2.9998e-08 |
| HCC70 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.9348 | -0.0227 | 0.0035 | 0.0000 | Inf | 0.040075 |
| HCC1806 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9819 | -0.0154 | 0.0035 | 0.0000 | Inf | -0.19348 |
| MDA-MB-231 | Ipatasertib | AKT | PI3K/mTOR | Inf | 0.9254 | 0.0073 | -0.0008 | 0.0000 | Inf | 0.28623 |
| HCC1806 | Ipatasertib | AKT | PI3K/mTOR | Inf | 0.9450 | 0.0145 | -0.0020 | 0.0000 | Inf | 0.32254 |
| PDX1258 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0159 | -0.0479 | 0.0014 | 0.0000 | Inf | -18.593 |
| MDA-MB-134-VI | Dasatinib | BCR/ABL | MAPK/nRTK | Inf | 0.8878 | -0.0289 | 0.0187 | 0.0000 | Inf | 0.37857 |
| SUM159PT | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9906 | -0.0088 | -0.0001 | 0.0000 | Inf | -0.54094 |
| CAL-51 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9105 | -0.0094 | 0.0003 | 0.0000 | Inf | 0.56048 |
| SUM159PT | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.6876 | 0.3173 | -0.0017 | 0.0000 | Inf | 0.45421 |
| MDA-MB-231 | A-1210477 | Mcl-1 | Misc | Inf | 0.9569 | 0.0519 | 0.0034 | 0.0000 | Inf | -8.5977e-09 |
| MDA-MB-436 | Dasatinib | BCR/ABL | MAPK/nRTK | Inf | 0.6528 | 0.1022 | 0.0098 | 0.0000 | Inf | 0.40773 |
| CAL-51 | A-1210477 | Mcl-1 | Misc | Inf | 0.9919 | 0.0073 | 0.0004 | 0.0000 | Inf | 0.00046652 |
| PDX1258 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9970 | -0.0328 | 0.0026 | 0.0000 | Inf | -2.2747 |